NCT06429345View on ClinicalTrials.gov

Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

PHASE4RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

October 1, 2024

Study Completion Date

November 1, 2024

Conditions
Contrast-induced Nephropathy
Interventions
DRUG

Coenzyme Q10 100 Milligrams Oral Capsule

Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.

DRUG

Placebo

placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.

Trial Locations (2)

Unknown

RECRUITING

Ain Shams university hospitals, Cairo

NOT_YET_RECRUITING

Ramy Mohamed Mostafa, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER